Posted by Michael Wonder on 11 Jan 2026
Aquestive Therapeutics announces regulatory development for Anaphylm (dibutepinephrine) sublingual film
9 January 2026 - Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time.
Aquestive Therapeutics today provided an update on the regulatory approval of Anaphylm and its business.
